GKIM
PHAT icon

GW&K Investment Management’s Phathom Pharmaceuticals PHAT Stock Holding History

GW&K Investment Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Buy
2,166,838
+745,729
+52% +$8.51M 0.18% 195
2026
Q1 		$15.8M Buy
1,421,109
+114,431
+9% +$1.45M 0.14% 229
2025
Q4 		$21.7M Buy
1,306,678
+162,348
+14% +$2.32M 0.19% 196
2025
Q3 		$13.5M Buy
1,144,330
+95,858
+9% +$989K 0.12% 240
2025
Q2 		$10.1M Sell
1,048,472
-55,836
-5% -$309K 0.09% 249
2025
Q1 		$6.92M Buy
1,104,308
+1,503
+0.1% +$9.13K 0.06% 265
2024
Q4 		$8.96M Sell
1,102,805
-23,278
-2% -$288K 0.08% 263
2024
Q3 		$20.4M Buy
1,126,083
+525,640
+88% +$7.35M 0.17% 201
2024
Q2 		$6.18M Buy
600,443
+32,417
+6% +$334K 0.06% 270
2024
Q1 		$6.03M Buy
568,026
+6,536
+1% +$55.5K 0.05% 269
2023
Q4 		$5.13M Sell
561,490
-15,960
-3% -$138K 0.05% 266
2023
Q3 		$5.99M Sell
577,450
-14,938
-3% -$205K 0.06% 260
2023
Q2 		$8.48M Sell
592,388
-6,460
-1% -$74.5K 0.08% 241
2023
Q1 		$4.28M Buy
598,848
+4,691
+0.8% +$41.2K 0.04% 276
2022
Q4 		$6.67M Buy
594,157
+998
+0.2% +$10.3K 0.07% 242
2022
Q3 		$6.57M Buy
593,159
+99,709
+20% +$950K 0.07% 214
2022
Q2 		$4.17M Buy
493,450
+13,808
+3% +$142K 0.04% 246
2022
Q1 		$6.53M Buy
479,642
+96,090
+25% +$1.55M 0.06% 233
2021
Q4 		$7.54M Buy
383,552
+158,629
+71% +$3.73M 0.06% 231
2021
Q3 		$7.22M Sell
224,923
-4,495
-2% -$149K 0.06% 232
2021
Q2 		$7.77M Buy
229,418
+29,900
+15% +$1.07M 0.07% 236
2021
Q1 		$7.49M Buy
+199,518
New +$8.35M 0.07% 233

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

GW&K Investment Management's PHAT Position: Q2 2026 in Review

GW&K Investment Management increased its Phathom Pharmaceuticals (PHAT) stake by 52% in Q2 2026, buying an estimated $8.51M and bringing the position to 2,166,838 shares worth $23.5M. The position accounts for 0.18% of the portfolio, ranked #195.

GW&K Investment Management first reported a position in PHAT in Q1 2021 and has held it in 22 quarters since. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • GW&K Investment Management held 2,166,838 shares of Phathom Pharmaceuticals worth $23.5M as of Q2 2026.
  • GW&K Investment Management bought 745,729 Phathom Pharmaceuticals shares in Q2 2026, an estimated $8.51M.
  • Phathom Pharmaceuticals made up 0.18% of GW&K Investment Management's portfolio in Q2 2026, its #195 holding.
  • GW&K Investment Management first reported a position in Phathom Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.